G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene is not associated with the risk of coronary artery disease among Chinese in Taiwan

Acta Cardiologica Sinica

Volumn 22, Issue 3, 2006, Pages 148-153

  Hsu, Lung An ^a   Ko, Yu Lin ^a   Chang, Chi Jen ^a   Wang, Chun Li ^a   Ho, Wan Jing ^a   Ko, Yu Shien ^a   Hsu, Tsu Shiu ^a   Chen, Wei Jan ^a   Cheng, Nye Jan ^a   Kuo, Chi Tai ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Coronary disease; Cytochromes P450; Polymorphism

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 CYP2J2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CHINESE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; TAIWAN;

EID: 33749677938     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Wu S, Moomaw CR, Tomer KB, et al. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 1996; 271:3460-8.
2. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999;285:1276-9.
3. Zeldin DC, Foley J, Ma J, et al. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance. Mol Pharmacol 1996;50:1111-7.
4. Zeldin DC, Foley J, Boyle JE, et al. Predominant expression of an arachidonate epoxygenase in islets of Langerhans cells in human and rat pancreas. Endocrinology 1997;138:1338-46.
5. Zeldin DC, Foley J, Goldsworthy SM, et al. CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance. Mol Pharmacol 1997;51:931-43.
6. Chacos N, Capdevila J, Falck JR, et al. The reaction of arachidonic acid epoxides (epoxyeicosatrienoic acids) with a cytosolic epoxide hydrolase. Arch Biochem Biophys 1983;223:639-48.
7. Zeldin DC, Kobayashi J, Falck JR, et al. Regio- and enantiofacial selectivity of epoxyeicosatrienoic acid hydration by cytosolic epoxide hydrolase. J Biol Chem 1993;268:6402-7.
8. Oltman CL, Weintraub NL, VanRollins M, et al. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 1998; 83:932-9.
9. Campbell WB, Harder DR. Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 1999;84:484-8.
10. Wu S, Chen W, Murphy E, et al. Molecular cloning, expression, and functional significance of a cytochrome P450 highly expressed in rat heart myocytes. J Biol Chem 1997;272:12551-9.
11. 2+ channels and contraction in mammalian heart ecus. J Physiol 1998;508:777-92.
12. Chen J, Capdevila JH, Zeldin DC, Rosenberg RL. Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol 1999;55:288-95.
13. Campbell WB, Gebremedhin D, Pratt PF, Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 1996;78:415-23.
14. Fisslthaler B, Popp R, Kiss L, et al. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999;401:493-7.
15. Node K, Ruan XL, Dai J, et al. Activation of Galpha s mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoic acids. J Biol Chem 2001;276:15983-9.
16. Yang B, Graham L, Dikalov S, et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol 2001;60:310-20.
17. King LM, Ma J, Srettabunjong S, et al. Cloning of CYP2J2 gene and identification of functional polymorphisms. Mol Pharmacol 2002;61:840-52.
18. Spiecker M, Darius H, Hankeln T, et al. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004;110:2132-6.
19. Ko YL, Ko YS, Wang SM, et al. The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 1998;141:259-64.
20. Hsu LA, Ko YL, Wang SM, et al. The C677T mutation of the methylenetetrahydrofolate reductase gene is not associated with the risk of coronary artery disease or venous thrombosis among Chinese in Taiwan. Hum Hered 2001;51:41-5.
21. Wang CL, Hsu LA, Ko YS, et al. Lack of association between the Glu298Asp variant of the endothelial nitric oxide synthase gene and the risk of coronary artery disease among Taiwanese. J Formas Med Assoc 2001;100:736-40.
22. Wang H, Jiang Y, Liu Y, et al. CYP2J2*7 single nucleotide polymorphism in a Chinese population. Clin Chim Acta 2006; 365(1-2):125-8.
23. Lee SS, Jeong HE, Liu KH, et al. Identification and functional characterization of novel CYP2J2 vaiants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenet Genomics 2005;15:105-13.
24. King LM, Gainer JV, David GL, et al. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet Genomics 2005;15:7-13.
25. McGiff JC. Cytochrome P-450 metabolism of arachidonic acid. Annu Rev Pharmacol Toxicol 1991;31:339-69.
26. Capdevila JH, Falck JR, Harris RC. Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 2000; 41:163-81.